Is LifeVantage Corp. overvalued or undervalued?

As of 4 September 2025, the valuation grade for LifeVantage Corp. has moved from expensive to fair, indicating a more favorable assessment of its market position. The company appears to be fairly valued based on its current metrics, with a P/E ratio of 17, a Price to Book Value of 4.63, and an EV to EBITDA ratio of 8.48. In comparison to peers, LifeVantage's P/E ratio is significantly lower than Chromadex Corp.'s 39.82 and USANA Health Sciences, Inc.'s 16.23, suggesting that it is relatively undervalued within its industry.
Despite recent challenges reflected in its stock performance, where it has underperformed against the S&P 500 in the year-to-date and one-month periods, it has shown strong growth over the three-year horizon with a return of 183.85% compared to the S&P 500's 70.41%. This long-term performance, coupled with a favorable valuation, supports the conclusion that LifeVantage Corp. is fairly valued at this time.